Anticancer combinations

Abstract

Provided herein, inter alia, are compositions and kits comprising a bacterial cell and a tumor penetrating agent. Also provided are methods of treating cancer in a subject including the step of administering to the subject an effective amount of a bacterial cell and a tumor penetrating agent. Provided are methods of stimulating an immune system in a subject. The methods include administering to the subject an effective amount of a bacterial cell and a tumor penetrating agent. Also provided are methods of enhancing delivery of an anti-cancer agent to a tumor cell including the step of contacting the tumor cell with a bacterial cell, a tumor penetrating agent and an anti-cancer agent.

1 . A method of treating cancer in a subject comprising administering to the subject a combined effective amount of a bacterial cell and a tumor penetrating agent, wherein administration treats the cancer in the subject. 
     
     
         2 . The method of  claim 1 , wherein the combined effective amount is a combined synergistic amount. 
     
     
         3 . A method of stimulating an immune system in a subject comprising administering to the subject a combined effective amount of a bacterial cell and a tumor penetrating agent, wherein administration of the bacterial cell and the tumor penetrating agent stimulates the immune system of the subject. 
     
     
         4 . The method of  claim 3 , wherein the immune response is an anti-cancer immune response. 
     
     
         5 . The method of  claim 1 , further comprising administering to the subject an anti-cancer agent. 
     
     
         6 . (canceled) 
     
     
         7 . A method of enhancing delivery of an anti-cancer agent to a tumor cell comprising contacting the tumor cell with a bacterial cell, a tumor penetrating agent and an anti-cancer agent, wherein contacting the tumor cell with the bacterial cell and cell penetrating agent enhances delivery of the anti-cancer agent. 
     
     
         8 . The method of  claim 7 , wherein the anti-cancer agent is selected from the group consisting of a small molecule, a nucleic acid, a polypeptide, and an antibody. 
     
     
         9 . The method of  claim 1 , wherein the bacterial cell is a  Salmonella  bacterial cell. 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 9 , wherein the  Salmonella  bacterial cell is selected from the group consisting of YS1646 (ATCC #202165), RE88, LH430, SL7207, χ8429, χ8431 an χ8468. 
     
     
         12 . The method of  claim 1 , wherein the bacterial cell comprises an antisense nucleic acid. 
     
     
         13 . (canceled) 
     
     
         14 . The method of  claim 12 , wherein the antisense nucleic acid targets an immunosuppressive target. 
     
     
         15 . The method of  claim 14 , wherein the immunosuppressive target is STAT3, IDO1, IDO2, Arginase 1, iNOS, CTLA-4, TGF-β, IL-10, pGE2 or VEGF. 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 12 , wherein the antisense nucleic acid is selected from the group consisting of SEQ ID NO:3-31. 
     
     
         19 . The method of  claim 1 , wherein the tumor penetrating agent is a hyaluronidase polypeptide. 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . A composition comprising a  Salmonella  bacterial cell and a hyaluronidase polypeptide. 
     
     
         25 . (canceled) 
     
     
         26 . The composition of  claim 24 , wherein the  Salmonella  bacterial cell is selected from the group consisting of YS1646 (ATCC #202165), RE88, LH430, SL7207, χ8429, χ8431 an χ8468. 
     
     
         27 . The composition of  claim 24 , wherein the bacterial cell comprises an antisense nucleic acid. 
     
     
         28 . (canceled) 
     
     
         29 . The composition of  claim 27 , wherein the antisense nucleic acid targets an immunosuppressive target selected from STATS, IDO1, IDO2, Arginase 1, iNOS, CTLA-4, TGF-β, IL-10, PGE2 and VEGF. 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . The composition of  claim 27 , wherein the antisense nucleic acid is selected from the group consisting of SEQ ID NO:3-31. 
     
     
         34 . (canceled) 
     
     
         35 . (canceled) 
     
     
         36 . (canceled) 
     
     
         37 . The composition of  claim 24 , further comprising an anti-cancer agent. 
     
     
         38 . (canceled) 
     
     
         39 . (canceled) 
     
     
         40 . (canceled) 
     
     
         41 . (canceled)